Clinical trial · Observational
Survival Outcomes of Residual Disease in Triple-Negative Breast Cancer
Survival Outcomes of Residual Disease in Patients With Triple-Negative Breast Cancer Following Neoadjuvant Therapy: A Retrospective Cohort Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer associated with a poor prognosis. Although neoadjuvant therapy improves outcomes in patients who achieve a pathological complete response, the presence of residual disease after treatment remains associated with an increased risk of recurrence and death. This retrospective cohort study aims to evaluate the survival outcomes of patients with residual disease following neoadjuvant therapy for TNBC and to assess the association between clinicopathological characteristics and survival outcomes, including disease-free survival and overall survival
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Triple-Negative Breast Cancer (TNBC) | Triple-Negative Breast Carcinoma | ALIAS | 0.85 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Chemo-radiotherapy alone | Procedure | — | UNRESOLVED |
| Not applicable- observational study | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Disease free survival
- timeFrame
- Up to 3 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Female patients aged ≥18 years. Histologically confirmed triple-negative breast cancer (TNBC). Received standard neoadjuvant systemic therapy. Underwent definitive breast surgery after completion of neoadjuvant therapy. Availability of postoperative pathological assessment documenting residual disease or pathological complete response (pCR). Complete clinical, pathological, treatment, and follow-up data available in the medical records. Exclusion Criteria: * Patients with metastatic disease at initial diagnosis. Patients who did not complete neoadjuvant therapy or did not undergo definitive surgery. Patients with incomplete or missing essential clinical, pathological, or follow-up data. Patients with a history of another primary malignancy that could affect survival analysis.
References
Publications (0)
Data not yet available